Arcellx, Inc. (ACLX)

Market Cap	3.99B
Revenue (ttm)	56.98M
Net Income (ttm)	-187.99M
Shares Out	55.46M
EPS (ttm)	-3.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	357,844
Open	70.70
Previous Close	72.52
Day's Range	66.52 - 71.61
52-Week Range	47.86 - 107.37
Beta	0.28
Analysts	Strong Buy
Price Target	114.75 (+59.38%)
Earnings Date	Aug 7, 2025

About ACLX

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2022
• Employees: 163
• Stock Exchange: NASDAQ
• Ticker Symbol: ACLX
• Website: https://www.arcellx.com

Financial Performance

In 2024, Arcellx's revenue was $107.94 million, a decrease of -2.16% compared to the previous year's $110.32 million. Losses were -$107.35 million, 51.9% more than in 2023.

Analyst Forecast

According to 14 analysts, the average rating for ACLX stock is "Strong Buy." The 12-month stock price target is $114.75, which is an increase of 59.38% from the latest price.

Price Target

$114.75

(59.38% upside)

Analyst Consensus: Strong Buy